UNSPSC 51121566: Nadolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FEN504330V. European Medicines Agency schedules Nadolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09111MIG. Nadolol generally arises in the molecular formula C17H27NO4.

UNSPSC 51121566 Nadolol, a Commodity code, covers pharmaceutical procurement by state and local governments, currently focused on emergency-response medications and multi-source generic pharmaceuticals supplied through authorized wholesalers. State and local buyers under this code include city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope spans both single-line-item medication orders for emergency medical services and broad-based generic pharmaceutical contracting that covers multiple drugs across authorized distribution channels. Nadolol procurement appears embedded within larger emergency-life-support or multi-drug cooperative agreements rather than as a standalone item, reflecting how state and local governments typically source individual pharmaceuticals as part of comprehensive medication supply contracts.

Recent activity spans Florida, Texas, and a multistate purchasing region anchored in Minnesota and Oregon. The City of Tampa's Purchasing Department issued an IFB (sealed-bid solicitation 26P00188) in April 2026 for Advanced Life Support Medications including specific vials and injections for Tampa Fire Rescue, with a contract value of $40,000.00 and a response deadline of April 8, 2026; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 exploring direct-to-manufacturer prescription contracting outside traditional pharmacy benefit managers and wholesalers—an exploratory market-intelligence phase intended to shape future formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC; pricing evaluation weighted heavily on competitiveness (75 percent) with contract effectiveness targeted for July 1, 2026.